Bisphosphonates for advanced prostate cancer
S Macherey, I Monsef, F Jahn, K Jordan… - Cochrane Database …, 2017 - cochranelibrary.com
Background The prevalence and incidence of pain and skeletal complications of metastatic
bone disease such as pathologic fractures, spinal cord compression and hypercalcemia is …
bone disease such as pathologic fractures, spinal cord compression and hypercalcemia is …
Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline
CL Shapiro, C Van Poznak, C Lacchetti… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE The aim of this work is to provide evidence-based guidance on the management
of osteoporosis in survivors of adult cancer. METHODS ASCO convened a multidisciplinary …
of osteoporosis in survivors of adult cancer. METHODS ASCO convened a multidisciplinary …
Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a cancer care Ontario guideline
PURPOSE In 2017, Cancer Care Ontario's Program in Evidence-Based Care released the
Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline. This guideline …
Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline. This guideline …
Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer
K Miller, GG Steger, D Niepel, D Lüftner - Prostate cancer and prostatic …, 2018 - nature.com
Background Patients with prostate cancer are at risk of impaired bone health. Prostate
cancer has a propensity to metastasize to bone, after which patients are at risk of skeletal …
cancer has a propensity to metastasize to bone, after which patients are at risk of skeletal …
[HTML][HTML] SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant …
J Chen, Z Wu, W Ding, C Xiao, Y Zhang, S Gao… - Theranostics, 2020 - ncbi.nlm.nih.gov
Until recently, there have been limited options for patients with bone metastatic castration-
resistant prostate cancer (BmCRPC) following the failure of or development of resistance to …
resistant prostate cancer (BmCRPC) following the failure of or development of resistance to …
The risk of fragility fractures in men with prostate cancer treated with androgen deprivation therapy
MM van Oostwaard, CE Wyers, JHM Driessen… - Osteoporosis …, 2024 - Springer
Abstract Summary Androgen Deprivation Therapy (ADT) increases long-term fracture risk in
prostate cancer. Our study showed a higher fracture risk within six months of ADT use, and …
prostate cancer. Our study showed a higher fracture risk within six months of ADT use, and …
High‐dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT
Background Androgen deprivation therapy (ADT) inhibits prostate cancer growth. However,
ADT causes loss of bone mineral density (BMD) and an increase in fracture risk; effective …
ADT causes loss of bone mineral density (BMD) and an increase in fracture risk; effective …
[HTML][HTML] Development of a multidisciplinary care pathway for fracture prevention in men with prostate cancer at initiation of androgen deprivation therapy
MM van Oostwaard, JP van den Bergh… - Cancers, 2024 - mdpi.com
Simple Summary Men with prostate cancer undergoing Androgen Deprivation Therapy
(ADT) have an increased risk of fractures. Despite this risk, fracture risk assessment is often …
(ADT) have an increased risk of fractures. Despite this risk, fracture risk assessment is often …
UPDATE–Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies
A Kokorovic, AI So, H Serag, C French… - Canadian …, 2021 - pmc.ncbi.nlm.nih.gov
2. Methods EmBASE and Medline databases were accessed to identify all relevant articles
focused on adverse events related to ADT from inception to December 2020. The following …
focused on adverse events related to ADT from inception to December 2020. The following …
[HTML][HTML] Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies
A Kokorovic, AI So, H Serag, C French… - Canadian Urological …, 2021 - ncbi.nlm.nih.gov
2. Methods EmBASE and Medline databases were accessed to identify all relevant articles
focused on adverse events related to ADT from inception to December 2020. The following …
focused on adverse events related to ADT from inception to December 2020. The following …